Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine

Jacqueline V. Aredo, Sukhmani K. Padda

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

The discovery of genomic alterations that drive the development and progression of non-small cell lung cancer (NSCLC) has transformed how we treat metastatic disease. However, the promise of precision medicine remains elusive for the most commonly mutated oncogene in NSCLC, KRAS. This is perhaps due to the substantial heterogeneity within the broader genomic context of KRAS-mutant NSCLC. At this time, approaches for treating metastatic KRAS-mutant NSCLC mirror those for treating NSCLC that lacks a known driver mutation, including standard chemotherapeutic and immunotherapeutic approaches. Ongoing research aims to define further subgroups of KRAS-mutant NSCLC based on mutation subtype and co-occurring mutations. These efforts offer the potential to optimize standard-of-care regimens within these emerging subgroups and harness innovative strategies to realize precision medicine in this setting.

Original languageEnglish
Article number43
Pages (from-to)43
JournalCurrent Treatment Options in Oncology
Volume19
Issue number8
DOIs
StatePublished - Aug 1 2018

Keywords

  • Co-occurring mutation
  • Immunotherapy
  • KRAS mutation
  • Lung cancer
  • Precision medicine

Fingerprint

Dive into the research topics of 'Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine'. Together they form a unique fingerprint.

Cite this